Oncternal Therapeutics, Inc. announced the initiation of its Phase 3 global registrational study of zilovertamab, ZILO-301 (NCT05431179), for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL). The Company obtained its first Institutional Review Board (IRB) approval for the study and expects to promptly begin patient screening and enrollment.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.5 USD | -3.19% | -9.67% | -20.74% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.74% | 25.99M | |
+46.48% | 56.65B | |
-6.70% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.25% | 26.75B | |
-21.63% | 19.03B | |
+0.60% | 12.28B | |
+23.59% | 12.26B | |
+27.68% | 12.04B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics, Inc Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL